[BLCM] Bellicum Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 14.61 Change: 0.99 (7.27%)
Ext. hours: Change: 0 (0%)

chart BLCM

Refresh chart

Strongest Trends Summary For BLCM

BLCM is in the medium-term down -22% below S&P in 2 months and down -51% in 5 months and down -53% below S&P in 7 months. In the long-term down -84% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-2.81 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -93.99% Sales Growth - Q/Q-93.99% P/E-4.03
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-43.58% ROE-44.27% ROI
Current Ratio69.87 Quick Ratio Long Term Debt/Equity Debt Ratio0.01
Gross Margin Operating Margin-3029.56% Net Profit Margin-4346.19% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-10 K Cash From Investing Activities-930 K Cash From Operating Activities-7.03 M Gross Profit
Net Profit-7.76 M Operating Profit-7.81 M Total Assets188.27 M Total Current Assets185.01 M
Total Current Liabilities2.65 M Total Debt Total Liabilities2.91 M Total Revenue110 K
Technical Data
High 52 week9.93 Low 52 week3.42 Last close3.42 Last change-6.3%
RSI30 Average true range0.41 Beta1.53 Volume289.04 K
Simple moving average 20 days-16.36% Simple moving average 50 days-22.89% Simple moving average 200 days-47.99%
Performance Data
Performance Week-8.8% Performance Month-20.28% Performance Quart-46.23% Performance Half-57.99%
Performance Year-58.75% Performance Year-to-date-59.33% Volatility daily4.68% Volatility weekly10.46%
Volatility monthly21.43% Volatility yearly74.24% Relative Volume166.33% Average Volume436.69 K
New High New Low

News

2018-12-27 09:47:02 | Bellicum Pharmaceuticals Enters Oversold Territory

2018-12-24 10:08:03 | Jazz JAZZ Falls as Sleep Drug Gets Extended Review From FDA

2018-12-20 07:00:00 | Bellicum Pharmaceuticals Announces Appointment of Judith Klimovsky, M.D., to Board of Directors

2018-12-14 07:00:00 | Bellicum Reports Safety Results and Promising Activity of Its Controlled CAR-T Candidate BPX-601 in Patients with Advanced Pancreatic Cancer at ESMO-IO

2018-12-13 07:00:00 | Bellicum Pharmaceuticals Appoints Atabak Mokari as Chief Financial Officer

2018-12-11 09:22:02 | Novan Announces Top-Line Data From Mid-Stage Molluscum Study

2018-12-02 10:30:00 | Bellicum Announces Data Presentation at ASH 2018 Demonstrating Low Rates of Cancer Recurrence in Pediatric AML and ALL Patients Treated with Rivo-cel

2018-12-01 14:00:00 | Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant

2018-12-01 12:00:00 | Bellicum Announces Favorable Interim Event-Free Survival Data for Rivo-cel Treated Patients in Presentation at ASH 2018

2018-11-28 08:30:00 | Recent Analysis Shows Bellicum Pharmaceuticals, NetEase, Nice, Match Group, SpartanNash, and Adaptimmune Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth

2018-11-27 07:00:00 | Bellicum Pharmaceuticals to Host Analyst and Investor Event and Webcast on Monday, December 3

2018-11-22 11:53:03 | Before You Buy Bellicum Pharmaceuticals Inc NASDAQ:BLCM, Consider Its Volatility

2018-11-07 07:00:00 | Bellicum Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference

2018-11-06 18:00:11 | Bellicum Pharmaceuticals BLCM Reports Q3 Loss, Tops Revenue Estimates

2018-11-06 16:01:00 | Bellicum Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

2018-11-01 09:01:00 | Bellicum Announces Data Presentations on Lead Product Candidate Rivo-cel and Controllable CAR Program at the 60th American Society of Hematology Annual Meeting

2018-10-17 08:30:00 | Report: Exploring Fundamental Drivers Behind Bellicum Pharmaceuticals, Social Reality, Exelixis, Edgewell Personal Care, Cronos Group, and Acacia Communications — New Horizons, Emerging Trends, and Upcoming Developments

2018-08-23 08:15:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Qurate Retail Group, Bellicum Pharmaceuticals, CannTrust, Iconix Brand Group, Maxwell Technologies, and AZUL SA — New Research Emphasizes Economic Growth

2018-08-18 11:40:34 | Edited Transcript of BLCM earnings conference call or presentation 7-Aug-18 9:00pm GMT

2018-08-07 19:50:11 | Bellicum Pharmaceuticals BLCM Reports Q2 Loss, Tops Revenue Estimates

2018-08-07 16:05:00 | Bellicum Pharmaceuticals Reports Second Quarter 2018 Financial Results

2018-08-07 15:00:00 | Bellicum Pharmaceuticals Inc to Host Earnings Call

2018-08-06 07:00:00 | Bellicum Pharmaceuticals Appoints Dr. Thierry Darcis as General Manager of Europe to Lead the Anticipated Launch of BPX-501

2018-08-04 13:04:00 | Here's Why Bellicum Pharmaceuticals Lost 13.8% in July

2018-07-31 07:00:00 | Bellicum Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018

2018-07-24 07:30:00 | Stock Performance Review on AVEO Pharma and Three Other Biotech Stocks

2018-07-16 16:25:00 | Bellicum Pharmaceuticals Announces Departure of Chief Financial Officer

2018-06-25 07:15:00 | Free Pre-Market Technical Pulse on AVEO Pharma and Three More Biotech Stocks

2018-06-15 07:45:00 | Analysis: Positioning to Benefit within Uranium Energy, Bellicum Pharmaceuticals, Tutor Perini, Maiden, Hill-Rom, and BioDelivery Sciences International — Research Highlights Growth, Revenue, and Consolidated Results

2018-06-12 08:20:00 | Today's Research Reports on Trending Tickers: Bellicum Pharmaceuticals and Sangamo Therapeutics

2018-05-30 07:00:00 | Bellicum Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

2018-05-29 07:00:00 | Bellicum Pharmaceuticals Appoints Shane Ward as General Counsel

2018-05-17 09:20:03 | Bellicum Announces Clinical Presentations on Lead Product Candidate BPX-501 at the 23rd Congress of the European Hematology Association

2018-05-15 07:00:00 | Bellicum Announces Oral Presentation on Dual-Switch CAR-T Technology at the 21st Annual Meeting of the American Society of Gene and Cell Therapy

2018-05-09 13:57:00 | Here's Why Bellicum Pharmaceuticals Is Jumping Higher Today

2018-05-08 16:01:00 | Bellicum Pharmaceuticals Reports First Quarter 2018 Financial Results

2018-04-23 08:20:00 | Today’s Research Reports on Stocks to Watch: TransUnion and Limelight Networks

2018-04-20 16:05:00 | Bellicum Pharmaceuticals Announces Closing of Public Offering

2018-04-17 18:26:59 | Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock

2018-04-17 14:33:00 | Here's Why Bellicum Pharmaceuticals Dropped as Much as 14.6% Today

2018-04-16 16:42:35 | Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock

2018-04-12 09:47:00 | Is Bellicum Pharmaceuticals Stock Now a Strong Buy?

2018-04-12 08:30:00 | Today’s Research Reports on Trending Tickers: Argos Therapeutics and Bellicum Pharmaceuticals

2018-04-12 07:51:28 | What Do Analysts Think About Bellicum Pharmaceuticals Inc’s NASDAQ:BLCM Long Term Outlook?

2018-04-11 16:17:49 | Bellicum Announces Clinical Hold Lifted on U.S. Studies of BPX-501

2018-04-09 11:10:00 | DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. And Reminds Investors With Losses In Excess of $50,000 To Contact The Firm

2018-04-09 10:11:00 | FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action Against Bellicum Pharmaceuticals, Inc. BLCM & Lead Plaintiff Deadline: April 9, 2018

2018-04-04 21:42:00 | APRIL 9 DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. And Reminds Investors With Losses In Excess of $50,000 To Contact The Firm

2018-04-03 14:25:00 | IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc.

2018-04-01 06:00:00 | FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Bellicum Pharmaceuticals, Inc. Nasdaq: BLCM To Contact The Firm